PubMed Health⌕ Search

Biomedical subjects

Guy Amit

Publications and source records attributed to Guy Amit.

16 recordsLinked to original sources
PubMed2006

Benefit of direct ambulance to coronary care unit admission of acute myocardial infarction patients undergoing primary percutaneous intervention.

BACKGROUND: Early reperfusion therapy in ST-segment elevation myocardial infarction (STEMI) patients improves left ventricular (LV) function and survival. However, emergency room (ER) triage may unnecessarily delay this time-dependent treatment. We sought to determine whether direct admission of STEMI patients from the mobile intensive care units to the intensive coronary care unit (ICCU), bypassing the ER, can shorten the time intervals for primary PCI (PPCI) and improve prognosis. METHODS: All STEMI patients who underwent PPCI between Jan-2002 to Nov-2005 were included. Baseline, clinical and time interval parameters were compared between groups. Mortality rates were obtained through the population register. RESULTS: Of 533 admissions, 115 (21%) were admitted directly to the ICCU. These patients were younger (mean (+S.D.) age of 58+13 years) than patients admitted via the ER (62+/-13 years, P<0.01) and had a lower proportion of women (9% vs. 22%, P<0.01), hypertension (45% vs. 62%, P<0.01) and diabetes (15% vs. 27%, P=0.01). Directly admitted patients had a substantially shorter median pain-to-balloon time (210 vs. 247 min, P=0.02) as well as s significantly shorter door-to-balloon time (70 vs. 94 min, P<0.01), a difference that was particularly pronounced during daytime (55 min vs. 90 min, P<0.01). There were no significant differences in LV function at 24 h as assessed by echocardiography or infarct size as determined by peak creatine kinase levels. We observed a trend towards reduced 30-day (5.2% vs. 9.8%, P=0.12) and 1-year (11.1% vs. 16.1%, P=0.25) mortality in directly admitted patients. CONCLUSIONS: Directly admitted STEMI patients differ from patients admitted via the ER; Direct ICCU admission, based on a pre-hospital ECG, can substantially shorten time to treatment.

Aged↗
PubMed2006

Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker.

BACKGROUND: Recent studies have shown conflicting results regarding a protective effect of statin therapy on atrial fibrillation (AF). HYPOTHESIS: We sought to determine whether statins are effective in reducing the risk of developing arrhythmia in a cohort of 264 patients (49% women, mean age [+/-standard deviation] 71 [+/-12] years) with permanent pacemakers who are at high risk for AF. METHODS: All patients who underwent implantation of a permanent pacemaker over a 3-year period were eligible for inclusion in the study. We excluded patients with AF at implantation, incomplete medication information, or less than a yearly follow-up visit. Atrial fibrillation was diagnosed by ECG documentation, pacemaker interrogation, and Holter monitoring. Statin treatment was verified through a central pharmacy-computerized database (for most patients) or by chart review. Of the 264 patients, 36% had coronary artery disease. RESULTS: Atrial fibrillation developed in 70 patients (26%) at a median of 359 days post pacemaker implantation. The incidence rate for the first occurrence of AF post pacemaker implantation among patients treated and not treated with statins was 10.5 versus 9.8 events per 100 patient-years, respectively (p = 0.81). Even after controlling for baseline differences, the hazard ratio (HR) for developing AF among statin users did not achieve statistical significance (HR = 0.59 [0.31-1.12]). CONCLUSIONS: We could not demonstrate that statin therapy had a protective effect against the risk of AF in patients implanted with a permanent pacemaker. The low prevalence of coronary artery disease in our patients may partly explain our results.

Aged↗
PubMed2006

Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.

BACKGROUND: The aim of this study was to test whether nitroprusside (NTP) injected intracoronary immediately before primary angioplasty for acute ST-elevation acute myocardial infarction (STEMI) prevents no-reflow and improves vessel flow and myocardial perfusion. METHODS: Ninety-eight patients presenting with STEMI were evenly randomized to receive either NTP (60 microg) or placebo. The drug was selectively injected into the infarct-related artery, distal to the occlusion, in a double-blind manner. The primary end points were postintervention angiographic corrected thrombolysis in myocardial infarction frame count and the proportion of patients with complete (>70%) ST-segment elevation resolution. Secondary end points included myocardial blush score and clinical outcome at 6 months follow-up. RESULTS: Mean (+/-SD) age was 62 (+/-12) years, and 87% were men. Baseline characteristics (excluding sex) did not differ between groups. The corrected thrombolysis in myocardial infarction frame count after angioplasty was 20.8 (+/-18.6) and 20.3 (+/-21.3) in patients given NTP and placebo, respectively (P = .78). Complete ST-segment resolution was achieved in 61.7% and 61.2% of NTP and placebo subjects, respectively (P = .96). The distribution of myocardial blush score did not differ between groups. At 6 months, the rate of target lesion revascularization, myocardial infarction, or death occurred in 6.3% of the NTP group and 20.0% of the placebo group (P = .05). CONCLUSIONS: In patients with STEMI, selective intracoronary administration of a fixed dose of NTP failed to improve coronary flow and myocardial tissue reperfusion but improved clinical outcomes at 6 months.

Aged↗
PubMed2006

[Diabetics with normal coronary arteries: clinical features and prognosis].

BACKGROUND: Diabetic patients comprise a large proportion of patients referred for coronary angiography. Only a minority of these patients will be found to have normal coronary arteries. AIM: To characterize diabetic patients who have angiographically normal coronary arteries. METHODS: Case-control study based on a computerized database. RESULTS: Using our computerized database, 13,342 consecutive patients referred for coronary angiography were identified. Diabetes mellitus was diagnosed in 24% of cases. Angiographically normal coronary arteries were found in 151 (5%) and 1228 (12%) of diabetic and non-diabetic patients, respectively (p<0.01). Diabetic patients with angiographically normal coronary arteries were matched with 155 diabetic patients who were catheterized on the same day but were found to have coronary artery disease. The median follow-up period was 1,774 days. The age of the diabetic patients with normal coronary arteries and diabetic patients with coronary artery disease was 5710 and 6410 years old respectively (p<0.01). A total of 39% and 60% of diabetic patients with normal coronary arteries and with coronary artery disease respectively were males, (p<0.01). Dyslipidemia was diagnosed in 66 (43%) of the diabetic patients with normal coronary arteries and 87 (57%) of the diabetic patients with coronary artery disease (P<0.01). After controlling for age and sex, the finding of normal coronary arteries was associated with decreased mortality (OR: 0.47, 95% CI 0.23 to 0.95). CONCLUSIONS: In diabetic patients referred for angiography it is unusual to find angiogrtaphically normal arteries. These patients have a relatively benign prognosis, as opposed to diabetic patients with evident coronary disease.

Aged↗
PubMed2006

[Automatic external defibrillator (AED) and public access defibrillation (PAD)].

Sudden death is a major public hazard and is usually caused by ventricular fibrillation (VF). Although in the majority of cases witnesses are to be found, resuscitation efforts are begun only in a minority of victims. The only treatment for VF is electrical shock and the time from collapse to resuscitation and defibrillation determine prognosis. Automated external defibrillator (AED) is a new device capable of effectively identifying and treating VF. It is unique in the sense that it can be operated by a non-medical operator following short training. Recent evidence of the survival benefit of AED utility is emerging. During the coming years, AEDs will be introduced to a growing number of hospitals and public places. This review summarizes the rationale for use, advantages, and disadvantages as well as the current status of AEDs and recommendations for placement of AEDs in Israel.

Arrhythmias, Cardiac↗
PubMed2005

Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.

BACKGROUND: Clopidogrel has largely replaced ticlopidine following coronary stent implantation. Recently, concern has been raised regarding the possibility of excess long term mortality in patients given clopidogrel rather than ticlopidine following coronary stenting. METHODS: We studied 1519 consecutive patients who underwent 2020 stent implantations and were discharged on dual antiplatelet regimens of either aspirin and ticlopidine or aspirin and clopidogrel given for up to 4 weeks. Thrombotic stent occlusion (TSO) was defined as ST elevation myocardial infarction in the stented artery territory associated with angiographic demonstration of complete stent occlusion. Mortality follow up was obtained for all patients by linkage to the Population Register. Follow up duration was 12 months. RESULTS: TSO occurred in 37 stents at a median of 29 days post procedure. Of these cases, six occurred in the ticlopidine group (0.7%) and 31 in the clopidogrel group (2.8%) (p<0.01). The median time to TSO was 34 days and 28 days in ticlopidine and clopidogrel treated patients, respectively (p<0.01). After controlling for multiple demographic, clinical and angiographic variables clopidogrel (vs. ticlopidine) treatment remained the sole predictor of TSO (OR: 5.4, 95% CI=1.2-24.1, p=0.028). Of even more concern, clopidogrel treatment was associated with an increased risk of 1 year mortality (OR: 1.8, 95% CI=1.2-2.8). CONCLUSIONS: Long term follow up after stent implantation in patients receiving the traditional 2-4 weeks course of dual antiplatelet therapy reveals increased rates of TSO and mortality in patients given clopidogrel as opposed to ticlopidine. Whether longer treatment with clopidogrel will change these observations deserves further study.

Aged↗
PubMed2004

What have the new definition of acute myocardial infarction and the introduction of troponin measurement done to the coronary care unit? Impacts on admission rate, length of stay, case mix and mortality.

OBJECTIVE: To assess the impact of the new American College of Cardiology/European Society of Cardiology definition of acute myocardial infarction (AMI) and the introduction of troponin measurement on the coronary care unit (CCU). METHODS: This was a retrospective cohort study performed in a tertiary care university hospital. All admissions to the CCU during the year before (period 1, year 2000, n = 1,134) and the year after (period 2, year 2002, n = 1,360) the introduction of troponin measurement and the new AMI definition were studied. We studied baseline characteristics, case load, distribution of admission diagnoses, management and outcome of patients in the two periods. RESULTS: There was a 20% increase in the number of CCU admissions, driven solely by a 141% increase in the burden of non-ST elevation AMI (NSTEMI) (p < 0.01). This increase was not a mere reflection of a change in diagnostic criteria, as the overall burden of non-ST elevation acute coronary syndromes (ACS) (NSTEMI + unstable angina) increased by 46%, suggesting referral of many more patients to the CCU. Despite a 42% increase in the number of angiograms performed, the proportion of ACS patients who had an angiogram declined. AMI patients in period 2 were older and had higher rates of coronary risk factors but had a higher chance of receiving a guideline-based therapy. Length of CCU stay decreased by a whole day for all ACS patients. 30-day mortality for AMI patients did not change significantly. CONCLUSIONS: The new AMI definition had a dramatic impact on the CCU case load, case mix and length of stay and on the ability to provide early coronary angiography.

Aged↗
PubMed2004

Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation.

The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.

Aged↗
PubMed2004

[Advanced cardiac life support--new answers to old dilemmas].

Sudden cardiac death is a major health hazard in the western world. During the year 2000 new guidelines for advanced cardiac life support were published. These comprehensive guidelines are based on international consensus and present the scientific evidence for each therapeutic intervention. During the following two years new studies investigating the treatment of cardiac arrest have provided new evidence for patients' care. The innovations in this area include the use of automatic external defibrillators, new drugs and measures to minimize brain injury. This review covers some of the new emerging issues in the treatment of cardiac arrest.

Brain Injuries↗
PubMed2003

Reperfusion arrhythmias during coronary angioplasty for acute myocardial infarction predict ST-segment resolution.

BACKGROUND: Despite early recanalization of an occluded infarct-related artery, myocardial reperfusion may remain impaired due to microvascular injury. Reperfusion arrhythmias may indicate successful microvascular reperfusion. METHODS: Microvascular reperfusion was assessed prospectively in 42 consecutive patients with ST-segment elevation acute myocardial infarction (AMI) by evaluation of the resolution of ST-segment elevation (<50% of initial level) immediately after successful coronary angioplasty. Patients were divided into two groups: those with ST resolution (n=24) and those without ST resolution (n=18). The presence of reperfusion arrhythmias immediately after recanalization was recorded. RESULTS: Patients with ST resolution were younger (54+/-12 years compared with 64+/-17 years, P=0.04), their pain-to-recanalization time was shorter (195+/-87 min compared with 294+/-179 min, P=0.05), they were less often diabetic (13% compared with 24%, P=0.05) and were more often given IIb/IIIa inhibitors (58% compared with 22%, P=0.02). Reperfusion arrhythmias were observed in 15 out of 24 patients with ST resolution (62%) but in only one out of 18 without ST resolution (5%) (P<0.01). Reperfusion arrhythmias included accelerated idioventricular rhythm, 13 (81%); multifocal ventricular premature beats, two (13%); and ventricular tachycardia, one (6%). The sensitivity and specificity of reperfusion arrhythmias for ST resolution were 62 and 95%, respectively. In a logistic regression model including age, time to treatment, diabetes, use of IIb/IIIa inhibitors and reperfusion arrhythmias, only the latter was found to be an independent predictor of ST resolution (P<0.01). CONCLUSION: Reperfusion arrhythmias following coronary angioplasty for AMI are a highly specific marker for ST resolution and may indicate successful microvascular reperfusion.

Adult↗
PubMed2003

[The use of cardiac troponins in acute coronary syndromes].

In patients with acute coronary syndromes cardiac troponins are sensitive markers of myocardial damage. The troponin complex comprises subunits C, T and I and is a major component in the process of myocyte contraction and relaxation. The T and I subunits have cardiac isoforms with distinct specific immunologic properties which distinguish them from similar subunits of non-cardiac muscle tissue. The high sensitivity and specificity of cardiac troponins make them the preferred biochemical markers for diagnosing acute myocardial infarction and for the triage of patients admitted with chest pain without ST segment elevation on the E.K.G. There is a correlation between cardiac troponin levels and prognosis in patients with acute coronary syndromes. In addition to their prognostic role, cardiac troponins play a role in selecting patients for contemporary treatments. Thus, their level can identify the patients most likely to benefit from treatments such as low molecular-weight heparin, IIb/IIIa receptor blockers and early angiography and coronary intervention. Recently, the American heart Association, the European Heart Society and the Israel Cardiology Society have published guidelines for the use of cardiac troponins. This review summarizes the current data regarding the use of cardiac troponins in the acute coronary syndromes.

Anticoagulants↗
PubMed2003

The association between hospital department, medical treatment and outcome in acute myocardial infarction.

BACKGROUND: Although the preferred management of a patient presenting with an acute myocardial infarction is in a coronary care unit, data based on discharge diagnoses in Israel indicate that many of these patients are treated outside of such units. OBJECTIVES: To compare the demographic and clinical characteristics, treatment and mortality of AMI patients treated inside and outside a CCU. METHODS: We compiled a registry of all patients admitted to three general hospitals in Haifa, Israel during January, March, May, July, September and November 1996. RESULTS: The non-CCU admission rate was 22%. CCU patients were younger (61.6 vs. 65.5 years), less likely to report a past AMI (18% vs. 34%), and arrived earlier at the emergency room. Non-CCU patients were more likely to present with severe heart failure (30 vs. 11%). Non-CCU patients received less aspirin (81 vs. 95%) and betablockers (62 vs. 80%). Upon discharge, these patients were less frequently prescribed beta-blockers and cardiac rehabilitation programs. CCU-treated patients had lower unadjusted mortality rates at both 30 days (odds ratio = 0.35) and in the long term (hazards ratio = 0.57). These ratios were attenuated after controlling for gender, age, type of AMI, and degree of heart failure (OR = 0.91 and HR = 0.78, respectively). CONCLUSIONS: A relatively high proportion of AMI patients were treated outside a CCU, with older and sicker patients being denied admission to a CCU. The process of evidence-based care by cardiologists was preferable to that of internists both during the hospital stay and at discharge. In Israel a significant proportion of all AMI admissions are initially treated outside a CCU. Emphasis on increasing awareness in internal medicine departments to evidence-based care of AMI is indicated.

Aged↗
PubMed2003

Door to balloon and door to needle: temporal trends in delays to reperfusion.

BACKGROUND: Reperfusion practices have changed markedly over the last few years with the introduction of primary percutaneous coronary intervention. This technique has gained growing popularity in Israel, but little published data are available regarding the delays to primary PCI in real life in this country. OBJECTIVES: To examine temporal trends in time to reperfusion achieved in a large tertiary center over 6 years. RESULTS: Between 1997 and 2002, 1,031 patients were admitted to our hospital with ST elevation myocardial infarction. Of these, 62% underwent thrombolysis and 38% primary PCI. The proportion of patients referred for primary PCI increased steadily, from 14% in 1997 to 68% in 2002. Door to treatment time among patients referred for thrombolysis or primary PCI was 54 +/- 42 and 117 +/- 77 minutes, respectively (P < 0.00001). The door to needle time in patients given thrombolysis remained virtually unchanged during the study period at around 54 minutes. In contrast, the door to balloon time progressively and substantially decreased, from 175 +/- 164 minutes in 1997 to 96 +/- 52 minutes in 2002. CONCLUSIONS: There is a steady increase in the proportion of patients referred for primary PCI than for thrombolysis. The door to needle delay in patients given thrombolysis substantially exceeds the recommended time. The door to balloon time has declined considerably but still slightly exceeds the recommended time. Given the inherent delay between initiation of lysis and arterial recanalization, it appears from our experience that PCI does not substantially delay arterial reperfusion as compared to thrombolysis. Efforts should continue to minimize delays to reperfusion therapy.

Analysis of Variance↗
PubMed2002

Nitrofurantoin-induced chronic active hepatitis.

BACKGROUND: Nitrofurantoin is a commonly prescribed urinary antiseptic. Hepatic injury has been associated with its use. OBJECTIVES: To present three patients in whom long-term exposure to the drug resulted in chronic active hepatitis; and to review the epidemiology, clinical immunology, histopathology, pathogenetic features and treatment of previously reported cases. RESULTS: Withdrawing nitrofurantoin once the diagnosis was suspected did not lead to remission of the liver disease and glucocorticoids had to be administered. One patient died of liver failure. CONCLUSIONS: Awareness of this unusual side effect of nitrofurantoin is important and caution should be taken before prescribing it. Over the past years new insight into the immune nature of this drug has emerged.

Aged↗
PubMedDate not supplied

Thrombocytopenia, immunoglobulin treatment, and acute myocardial infarction--a case report.

Platelets play a pivotal role in the pathophysiology of the acute coronary syndromes, and platelet inhibition is a cornerstone in the management of these patients. Patients with profound thrombocytopenia who present with an acute coronary syndrome present a difficult challenge. The authors report a patient with immune thrombocytopenic purpura who presented with acute myocardial infarction despite a very low platelet count and who sustained recurrent infarction after receiving immune globulin treatment. The best management of thrombocytopenic patients with acute coronary syndromes is uncertain, but extreme caution is needed before efforts are made to raise the platelet count in order to allow conventional treatment.

Coronary Angiography↗